AARTI DRUGS Latest Share Price (AARTIDRUGS)
TODAY IN ONE LINE
AARTIDRUGS rose 1.4% on above-average volume (1.9x avg), outperforming Nifty's 0.1% move.
With a market cap of ₹3,973.44 Cr., it trades at a P/E of 20.00. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
AARTI DRUGS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Reasonable ValuationTrading at a moderate P/E of 17.6x
- ●High Promoter HoldingPromoters hold 54.4% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 12.0% YoY
- ●Sales ContractionQuarterly sales dropped 10.7% YoY
- ●Promoter SellingPromoter holding decreased by 0.60% QoQ
Latest AARTI DRUGS News
What changed recently?
Recent events, corporate actions, and announcements.
AARTI DRUGS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for AARTI DRUGS, framed against the sector median so the premium or discount is obvious at a glance.
AARTI DRUGS trades at a P/E of 20.00× and P/B of 2.47×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
AARTI DRUGS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for AARTI DRUGS — derived from the latest tape, not yesterday's close.
AARTI DRUGS last traded at ₹431.65 with an intraday range of ₹426.2–₹443.75 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹431.65| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 476.63 | +44.98 | +10.42% |
| R3 | 459.08 | +27.43 | +6.36% |
| R2 | 451.42 | +19.77 | +4.58% |
| R1 | 441.53 | +9.88 | +2.29% |
| PIVOT | 433.87 | 2.22 | 0.51% |
| CURRENT | 431.65 | — | — |
| S1 | 423.98 | -7.67 | -1.78% |
| S2 | 416.32 | -15.33 | -3.55% |
| S3 | 406.43 | -25.22 | -5.84% |
| S4 | 388.88 | -42.77 | -9.91% |
AARTIDRUGS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹426.25–₹433
Trading Inside opening range
AARTI DRUGS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for AARTI DRUGS — consolidated or standalone — with margins, YoY growth and key ratios inline.
AARTI DRUGS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,973.44 Cr. and reported EPS of ₹5.57.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,387 | 2,565 ▲ 7.5% |
| Sales Growth YoY %Derived | -5.60% | 7.47% |
| Other Income | 16 | 2 ▼ 85.4% |
| Total Income | 2,403 | 2,568 ▲ 6.8% |
| 1,542 | 1,619 ▲ 5.0% | |
| Gross ProfitDerived | 845 | 947 ▲ 12.0% |
| Gross Margin %Derived | 35.40% | 36.90% |
| 558 | 637 ▲ 14.3% | |
| EBITDA (Operating Profit)Derived | 287 | 309 ▲ 7.7% |
| OPM %Derived | 12.03% | 12.05% |
| 92 | 101 ▲ 9.9% | |
| Profit Before Tax (PBT) | 212 | 211 ▼ 0.4% |
| 44 | 16 ▼ 63.5% | |
| Effective Tax %Derived | 20.62% | 7.57% |
| Total Profit for Period | 168 | 195 ▲ 16.0% |
| Less: Non-controlling Interests | -0 | 0 ▲ 133.0% |
| Net Profit (Owner's PAT)Derived | 168 | 195 ▲ 15.9% |
| Net Profit Margin %Derived | 7.04% | 7.60% |
| PAT Growth YoY %Derived | -1.90% | 15.91% |
| Earnings Per Share (EPS ₹) | 18.42 | 21.36 ▲ 16.0% |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 2 | 3 ▲ 101.3% |
| Total Expenses (incl. D&A & Interest) | 2,192 | 2,357 ▲ 7.5% |
| Material Cost % of RevenueDerived | 60.25% | 58.63% |
| Employee Cost % of RevenueDerived | 4.70% | 5.04% |
| Other Cost % of RevenueDerived | 18.67% | 19.81% |
| Interest Coverage (x)Derived | 6.45x | 7.19x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,263 | 1,561 ▲ 23.6% | 1,806 ▲ 15.7% | 2,155 ▲ 19.3% | 2,489 ▲ 15.5% | 2,716 ▲ 9.1% | 2,529 ▼ 6.9% | 2,387 ▼ 5.6% | 2,565 ▲ 7.5% | |
| Sales Growth YoY %Derived | — | 23.63% | 15.71% | 19.31% | 15.49% | 9.14% | -6.90% | -5.60% | 7.47% | |
| Other Income | 1 | 6 ▲ 488.6% | 1 ▼ 76.1% | 5 ▲ 206.1% | 11 ▲ 149.9% | 2 ▼ 80.7% | 4 ▲ 84.0% | 16 ▲ 306.0% | 2 ▼ 85.4% | |
| Total Income | 1,264 | 1,567 ▲ 24.0% | 1,808 ▲ 15.3% | 2,159 ▲ 19.5% | 2,500 ▲ 15.8% | 2,718 ▲ 8.7% | 2,533 ▼ 6.8% | 2,403 ▼ 5.1% | 2,568 ▲ 6.8% | |
783 | 1,060 ▲ 35.4% | 1,179 ▲ 11.2% | 1,321 ▲ 12.1% | 1,689 ▲ 27.8% | 1,889 ▲ 11.8% | 1,678 ▼ 11.2% | 1,542 ▼ 8.1% | 1,619 ▲ 5.0% | ||
| Gross ProfitDerived | 480 | 501 ▲ 4.4% | 627 ▲ 25.2% | 834 ▲ 32.9% | 800 ▼ 4.1% | 828 ▲ 3.5% | 851 ▲ 2.8% | 845 ▼ 0.7% | 947 ▲ 12.0% | |
| Gross Margin %Derived | 38.01% | 32.09% | 34.72% | 38.69% | 32.14% | 30.47% | 33.65% | 35.40% | 36.90% | |
281 | 294 ▲ 4.3% | 365 ▲ 24.4% | 397 ▲ 8.6% | 470 ▲ 18.6% | 522 ▲ 11.0% | 534 ▲ 2.4% | 558 ▲ 4.4% | 637 ▲ 14.3% | ||
| EBITDA (Operating Profit)Derived | 198 | 207 ▲ 4.5% | 262 ▲ 26.3% | 437 ▲ 66.9% | 329 ▼ 24.6% | 306 ▼ 7.2% | 316 ▲ 3.6% | 287 ▼ 9.3% | 309 ▲ 7.7% | |
| OPM %Derived | 15.72% | 13.28% | 14.50% | 20.29% | 13.24% | 11.25% | 12.52% | 12.03% | 12.05% | |
75 | 83 ▲ 10.0% | 87 ▲ 5.4% | 73 ▼ 16.0% | 71 ▼ 3.1% | 84 ▲ 18.1% | 85 ▲ 1.6% | 92 ▲ 7.9% | 101 ▲ 9.9% | ||
| Profit Before Tax (PBT) | 125 | 131 ▲ 5.2% | 185 ▲ 41.4% | 369 ▲ 99.2% | 270 ▼ 26.8% | 224 ▼ 17.0% | 236 ▲ 5.1% | 212 ▼ 10.1% | 211 ▼ 0.4% | |
42 | 41 ▼ 2.2% | 44 ▲ 6.3% | 89 ▲ 101.9% | 65 ▼ 26.7% | 58 ▼ 11.0% | 64 ▲ 10.6% | 44 ▼ 31.7% | 16 ▼ 63.5% | ||
| Effective Tax %Derived | 33.89% | 31.50% | 23.69% | 24.01% | 24.06% | 25.79% | 27.15% | 20.62% | 7.57% | |
| Total Profit for Period | 82 | 90 ▲ 9.0% | 141 ▲ 57.5% | 280 ▲ 98.3% | 205 ▼ 26.9% | 166 ▼ 18.8% | 172 ▲ 3.1% | 168 ▼ 2.0% | 195 ▲ 16.0% | |
| Less: Non-controlling Interests | — | — | -0 | -0 ▼ 600.0% | -0 ▼ 191.2% | 0 ▲ 216.8% | 0 ▲ 245.0% | -0 ▼ 135.7% | 0 ▲ 133.0% | |
| Net Profit (Owner's PAT)Derived | 82 | 90 ▲ 9.0% | 141 ▲ 57.6% | 280 ▲ 98.3% | 205 ▼ 26.9% | 166 ▼ 18.9% | 171 ▲ 3.1% | 168 ▼ 1.9% | 195 ▲ 15.9% | |
| Net Profit Margin %Derived | 6.52% | 5.75% | 7.83% | 13.01% | 8.24% | 6.12% | 6.78% | 7.04% | 7.60% | |
| PAT Growth YoY %Derived | — | 9.04% | 57.55% | 98.31% | -26.88% | -18.89% | 3.07% | -1.90% | 15.91% | |
| Earnings Per Share (EPS ₹) | 8.73 | 9.51 ▲ 8.9% | 15.17 ▲ 59.5% | 30.09 ▲ 98.4% | 22.14 ▼ 26.4% | 17.96 ▼ 18.9% | 18.65 ▲ 3.8% | 18.42 ▼ 1.2% | 21.36 ▲ 16.0% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% | 9 ▼ 1.2% | 9 ▲ 0.0% | 9 ▼ 0.6% | 9 ▲ 0.0% | 9 ▼ 0.7% | 9 ▼ 0.7% | 9 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | 1 ▲ 466.7% | 2 ▲ 78.8% | 3 ▲ 92.7% | 1 ▼ 80.1% | -2 ▼ 320.6% | 0 ▲ 104.0% | 2 ▲ 2550.0% | 3 ▲ 101.3% | |
| Total Expenses (incl. D&A & Interest) | 1,139 | 1,436 ▲ 26.1% | 1,622 ▲ 13.0% | 1,790 ▲ 10.4% | 2,230 ▲ 24.6% | 2,494 ▲ 11.8% | 2,297 ▼ 7.9% | 2,192 ▼ 4.6% | 2,357 ▲ 7.5% | |
| Material Cost % of RevenueDerived | 63.19% | 63.99% | 63.23% | 56.69% | 66.96% | 65.13% | 62.17% | 60.25% | 58.63% | |
| Employee Cost % of RevenueDerived | 4.59% | 3.90% | 3.84% | 3.74% | 3.33% | 3.39% | 4.05% | 4.70% | 5.04% | |
| Other Cost % of RevenueDerived | 17.70% | 14.91% | 16.39% | 14.67% | 15.57% | 15.83% | 17.09% | 18.67% | 19.81% | |
| Interest Coverage (x)Derived | 4.53x | 4.12x | 6.32x | 16.86x | 13.46x | 7.67x | 7.91x | 6.45x | 7.19x |
AARTI DRUGS segment analysis : revenue and profit mix.
Disclosed business segments at AARTI DRUGS with their share of revenue and profit, switchable between consolidated and standalone reporting.
AARTI DRUGS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for AARTI DRUGS.
Our AI distills the core fundamental drivers supporting AARTI DRUGS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
AARTI DRUGS's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
P/E ratio 17.65x significantly below peer median 39.03x, offering substantial valuation discount.
Promoter holding 54.43% signals strong founder commitment and long-term strategic stability.
Operating margin 9.44% competitive within pharma segment, with expansion trajectory evident.
Vertically integrated API manufacturing across pain, infection, cardiovascular, diabetes reduces costs.
ROE 12.05% and ROCE 10.64% demonstrate reasonable capital efficiency within operations.
Key Risks.
Latest quarterly EPS declined 12.2% YoY despite revenue growth, earnings pressure evident.
TTM EPS declined 12.0% YoY, indicating sustained earnings contraction trend.
5-year revenue growth 0% signals top-line stagnation and limited organic expansion.
Dividend yield 0.48% low, minimal income generation for shareholders.
Stock traded 26.5% below 52-week high of ₹534.55, signals investor sentiment weakness.
Flip Conditions.
Valuation risk. a P/E above 26 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
AARTI DRUGS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — AARTI DRUGS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
AARTI DRUGS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for AARTI DRUGS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
AARTI DRUGS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for AARTI DRUGS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in AARTI DRUGS stood at 46.1% of traded volume, against a 20-day average of 49.1%.
AARTI DRUGS announcements: results, concalls, ratings, M&A.
Filings AARTI DRUGS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
AARTI DRUGS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 139 documents below.
Copy of Newspaper Publication
Aarti Drugs Limited has informed the Exchange about Copy of Newspaper Publication
Updates
Aarti Drugs Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for FY 2025-26 '.
Shareholders meeting
Aarti Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2026
Copy of Newspaper Publication
Aarti Drugs Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026.
Investor decks & rating reports.
AARTI DRUGS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue AARTI DRUGS has declared, sequenced by announce and record date.
AARTI DRUGS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About AARTI DRUGS: business, sector, key facts.
What AARTI DRUGS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
AARTI DRUGS operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AARTIDRUGS, BSE: 524348.
Aarti Drugs Limited is an Indian pharmaceutical company established in 1984 and headquartered in Mumbai. Its core business revolves around the manufacturing and marketing of a diverse range of pharmaceutical products both domestically and internationally. This includes a significant portfolio of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and finished pharmaceutical formulations.
The company's API production encompasses a broad spectrum of therapeutic classes. They manufacture APIs for drugs used in treating pain and inflammation (e.g., diclofenac, nimesulide, aceclofenac), bacterial infections (e.g., ciprofloxacin, levofloxacin, moxifloxacin), fungal infections (e.g., fluconazole, ketoconazole), cardiovascular diseases (e.g., clopidogrel, raloxifene), and diabetes (e.g., metformin, pioglitazone, teneligliptin, vildagliptin). Additionally, they produce APIs for other therapeutic areas such as sleep disorders (zolpidem) and anti-anxiety medications (acamprosate).
Beyond APIs, Aarti Drugs also produces a substantial variety of pharmaceutical intermediates crucial in the synthesis of various drugs. These intermediates are supplied to other pharmaceutical companies for their own drug manufacturing processes. Specific examples include key intermediates for the production of Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem.
Further expanding its chemical capabilities, the company manufactures a range of specialty chemicals, including various benzene and toluene sulfonyl derivatives, as well as other organic chemicals utilized in the pharmaceutical and other chemical industries. This demonstrates a vertically integrated approach, providing Aarti Drugs with control over key raw materials and intermediates.
In summary, Aarti Drugs operates across multiple segments of the pharmaceutical value chain, from the synthesis of basic chemical building blocks to the manufacturing of complex APIs and the development of drugs across several therapeutic areas. Their diversified product portfolio and vertically integrated approach position them strongly within the Indian and international pharmaceutical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- ALBERT DAVID (ALBERTDAVD) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about AARTI DRUGS (AARTIDRUGS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of AARTI DRUGS (AARTIDRUGS)?
The current share price of AARTI DRUGS (AARTIDRUGS) is ₹431.65. Today, the stock has gained by ₹5.80 (1.36%), trading in a range of ₹426.20 to ₹443.75. The stock opened at ₹429.25 with a trading volume of 2,50,307 shares.
02Is AARTI DRUGS stock a good investment for long-term?
AARTI DRUGS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,973.44 Cr., P/E ratio of 20, ROE of 12.05%, and ROCE of 10.64%. The dividend yield stands at 0.46%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of AARTI DRUGS stock?
The 52-week high price of AARTI DRUGS (AARTIDRUGS) is ₹534.55, while the 52-week low is ₹318.95. Currently trading at ₹431.65, the stock is 35.33% above its 52-week low and 19.25% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy AARTI DRUGS stock at the current price?
Whether to buy AARTI DRUGS stock at ₹431.65 depends on multiple factors. The stock is currently trading with a P/E ratio of 20 and P/B ratio of 2.47. Today's performance shows a gain of 1.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of AARTI DRUGS and when is the next dividend?
AARTI DRUGS offers a dividend yield of 0.46%, which means for every ₹100 invested at the current price of ₹431.65, you can expect to receive approximately ₹0.46 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of AARTI DRUGS?
AARTI DRUGS's key financial metrics include: P/E Ratio: 20, P/B Ratio: 2.47, ROE: 12.05%, ROCE: 10.64%, Dividend Yield: 0.46%, EPS: ₹5.57, Book Value: ₹169.74, and Debt-to-Equity: 0.3. The company's market cap stands at ₹3,973.44 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is AARTI DRUGS stock performing today in the market?
AARTI DRUGS stock opened at ₹429.25 and is currently trading at ₹431.65, showing a gain of ₹5.80 (1.36%). The intraday high is ₹443.75 and low is ₹426.20. The trading volume stands at 2,50,307 shares, indicating moderate market participation today.
08What is the P/E ratio of AARTI DRUGS and what does it indicate?
AARTI DRUGS has a Price-to-Earnings (P/E) ratio of 20, which means investors are willing to pay 20.00 for every ₹1 of earnings. With an EPS of ₹5.57, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about AARTI DRUGS (AARTIDRUGS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.